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ABSTRACT 
Purpose: Age-related Macular Degeneration (AMD) has a strong genetic component 
with a major locus at 1q31, including the complement factor H gene (CFH). Detailed 
analyses of this locus have demonstrated the existence of one SNP haplotype block, 
carrying the CFH-402His allele, which confers increased risk to AMD, and two 
protective SNP haplotypes, one of them carrying a deletion of the CFHR1 and CFHR3 
genes (ΔCFHR3-CFHR1). The purpose of these studies was to evaluate the contribution of 
newly described CFHR1 alleles to the association of the 1q31 locus with AMD.  
Methods: 259 patients and 191 age-matched controls of Spanish origin were included 
in a transversal comparative case-control study using multivariate logistic regression 
analysis and ROC (Receiver Operating Characteristics) statistics to generate and to test 
models predictive for developing AMD. 
Results: We show for the first time that a particular CFHR1 allotype, CFHR1*A, is 
strongly associated with AMD (OR, 2.08; 95% CI, 1.59-2.73; P<0.0001) and illustrate a 
peculiar genotype-phenotype correlation between the CFHR1 alleles and different 
diseases that may have important implications for understanding the pathophysiology of 
AMD. We also show that CFHR1*A is in strong linkage disequilibrium with the CFH-
402His allele, which provides additional candidate variants within the major risk 
haplotype at 1q31 for being responsible of its association with AMD. Further, using the 
Spanish population as a model, we show that analysis of the CFHR1 genotypes provide 
sufficient information to delineate the individual risk to develop AMD.  
Conclusions: Our results support a relevant role of CFHR1 in AMD pathogenesis. 
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INTRODUCTION 
Age-related macular degeneration (AMD) is the most common cause of visual 
disability in the elderly in developed countries1. AMD is a multifactorial disease, 
influenced by age, ethnicity and a combination of environmental and genetic risk 
factors2. Genetic predisposition in AMD has been suggested based on familial 
segregation and twins studies. Several candidate genes with a relatively minor 
contribution and two major susceptibility loci (1q31, CFH/CFHR1/CFHR3; 10q26, 
HTRA1/ARMS2) that independently contribute to AMD disease risk have been 
identified by candidate region studies and whole genome association analyses3-10.  
The 10q26 locus includes two nearby genes, ARMS2 (age-related maculopathy 
susceptibility 2, also known as LOC387715)11 and HTRA1 (high-temperature 
requirement factor A1)11. The most studied SNP at this locus is rs10490924, which 
causes the Ala69Ser amino acid substitution in ARMS2, a protein located in the 
ellipsoid, a mitochondria-concentrated part of human photoreceptor cells. The risk-
associated allele ARMS2-69Ser is in strong linkage disequilibrium with a genetic variant 
resulting from a combination of a deletion and insertion (*372_815delins54) in the 3’ 
untranslated region of the ARMS2 mRNA, which affects the stability of the ARMS2 
mRNA and supports a role for ARMS2 in AMD pathogenesis11. 
Several independent studies have shown that the CFH-402His allele 
(rs1061170), at the CFH locus in 1q31, confers a significantly increased risk to AMD 
with an odds ratio (OR) between 2.1 and 7.43, 5-7. The association of CFH with AMD 
strengthened the implication of the complement system in the pathogenesis of AMD 5 
and prompted subsequent candidate gene approaches that resulted in the identification 
of additional associations of complement genes with AMD4, 9-10, 12-15. As a whole, these 
genetic data reinforced the concept that complement disregulation is a major player in 
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AMD pathogenesis. This conclusion is supported by the functional analysis of the 
AMD-associated SNPs in the CFH16, CFB17 and C318 genes. The CFH Tyr402His 
polymorphism has also been found to have functional implications. Notably, it alters the 
binding specificity of factor H for different glycosaminoglycans19-20 and decreases its 
binding to retinal pigment epithelial cells21 and Bruch membrane22. However, the 
physiological relevance of these observations is still unclear. 
Within the CFH gene, downstream of the Tyr402His polymorphism, there are 
three polymorphisms, a synonymous SNP in exon 11 (rs2274700) and two intronic 
SNPs (rs1410996 and rs7535263), showing stronger association with disease 
susceptibility than the CFH-402His variant14-15. These polymorphisms and the CFH 
402His variant form part of the same CFH haplotype conferring increased risk to AMD 
(haplotype H1)23. Two additional haplotypes in CFH gene (haplotypes H2 and H4) are 
markedly decreased in AMD and therefore have been described associated with lower 
risk to AMD13, 15, 24. CFH haplotype H2 carries the Ile62 factor H variant showing 
increased complement regulatory activity16, which likely confers lower risk to AMD by 
reducing complement activation. CFH haplotype H4 is also associated with decreased 
risk of AMD13, 25. Interestingly, this CFH haplotype is also unique because it carries a 
deletion of the CFHR1 and CFHR3 genes (ΔCFHR3-CFHR1)13. Although it has been 
indicated that CFHR1 and CFHR3 proteins have the potential to compete with factor H 
and interfere its complement regulatory activity, the potential benefit of the absence of 
CFHR1 and CFHR3 proteins is still puzzling as these two proteins are considered 
complement regulators26. Recently it has been proposed that complement activity is 
determined by a homeostatic balance between CFHR1, CFHR3 and factor H and that 
loss of CFHR1 and CFHR3, affecting local factor H binding, may increase local factor 
H-mediated regulation and protecting against AMD development 27.  
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Here we provide further insights into the gene variants encoded by the AMD 
locus at 1q31. We show that CFHR1*A, a recently described allele encoded by the 
CFHR1 gene, is associated with AMD and in strong LD with the CFH-402His allele. 
These data add to previous results and support a relevant role of CFHR1 in AMD 
pathogenesis. To further illustrate the relevance of the CFHR1 gene we tested the value 
of a model of disease risk based on the CFHR1 genotypes. We show that this model 
provides meaningful predictive values for the development of AMD that are comparable 
to those obtained with models based on SNPs at the CFH gene. 
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PATIENTS, MATERIALS AND METHODS 
Patients and Controls. 
Our study included 259 patients of Spanish origin with advanced AMD and a cohort of 
191 age-matched controls. Cases were recruited from the Department of 
Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain. The general 
inclusion criteria for the patients with advanced AMD and controls were as follows: age 
of 60 years or older; absence of other retinal diseases related to coroidal 
neovascularization (CNV), such as angioid streaks, a nevus in the macular area, 
toxoplasma scars, photocoagulation scars in the posterior pole, or polypoidal choroidal 
vasculopathy, and less than 6 dioptres of myopia. The inclusion criteria for patients with 
advanced AMD included drusen and a chorioretinal macular atrophy involving central 
macular or signs related CNV at least in one eye (category 4 of AREDS study)28. The 
inclusion criteria for controls were absence of drusen or no more than 5 small drusen 
(no exceeding 65 microns), absence of retinal pigment abnormalities in the macular 
area, absence of chorioretinal macular atrophy or any form of CNV, (category 1 of 
AREDS study)28.  All samples were obtained with informed consent in accordance with 
the Declaration of Helsinki and our institutional review boards. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood using standard procedures or from 
oral swabs using QIAcube (QIAGEN, Valencia, CA). DNA samples were genotyped 
for seven SNPs in four of the genes previously shown to be associated with AMD (CFH 
Ile62Val, CFH Tyr402His, CFH c.2237-543A>G, CFB Leu9His, CFB Arg32Gln/Trp, 
C3 Arg102Gly and ARMS2 Ala69Ser). The genotyping was performed using multiplex 
PCR and primer extension methodology (ABI Snapshot, Applied Byosistem, Foster 
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City, CA) in a 3730 automated sequencer (Applied Byosistem, Foster City, CA). The 
fragments were analyzed with the Applied Biosystems GeneMapper® Software v4.0. 
The analysis of the ΔCFHR3-CFHR1 polymorphism and the genotyping of CFHR1 was 
performed as described previously29. All the polymorphisms analyzed in this report 
were in Hardly-Weingberg equilibrium. 
 
Haplotype determinations 
Linkage disequilibrium analysis of the variants within CFH and CFHR1 polymorphic 
loci was performed using the MIDAS software30. Haplotype frequencies in the controls 
and patients cohorts were estimated using the expectation maximization algorithm 
implemented by the SNPstats software at the Web site: 
http://bioinfo.iconcologia.net/snpstats/start.htm. Calculation of p values between groups 
was performed by Pearson’s Chi-square test of association and considered significant if 
two sides p value <0.05. Odds ratios (OR) and 95% Confidence Intervals (CI) were also 
calculated. 
 
Statistical Analysis 
Statistical analyses were performed using the SPSS software for Windows version 14.0 
(Chicago, IL, USA). Allele frequencies differences between cases and controls were 
assessed by performing a Pearson’s χ2 test of association and OR and 95% CI were 
calculated. CFH, CFHR1, CFB and ARMS2 genotypes for each individual were 
included in a transversal comparative case-control study using multivariate logistic 
regression analysis and ROC (Receiver Operating Characteristics) statistics to generate 
and test models predictive for developing AMD based exclusively on the genotypes of 
the genes considered in the study. Cumulative risk scores (Z) were determined by the 
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equation Z=α+ΣβiXi where the regression coefficients α (constant) and βi (risk score 
specific for each genotype X) are taken directly form the multivariate logistic regression 
analysis. Probabilities of developing AMD (P) were calculated as P=eZ/(1+eZ) and were 
categorized in four risk groups: very low (P<25%), low (25%>P<50%), high 
(50%>P<75%) and very high (P>75%). A two sided p value <0.05 was considered 
statistically significant. 
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RESULTS 
The CFHR1*A allele is strongly associated with AMD. 
We have recently described a novel polymorphism of the CFHR1 gene with two alleles, 
CFHR1*A and CFHR1*B, encoding CFHR1 proteins that present different degree of 
similarity to factor H (Figure 1). The CFHR1*B allotype, with greater sequence 
similarity to factor H is strongly associated with atypical hemolytic uremic syndrome 
(aHUS), perhaps suggesting that increased competition between CFHR1*B and factor H 
decreases protection of cellular surfaces against complement damage29. To study 
whether this novel CFHR1 polymorphism also influences predisposition to AMD we 
genotyped our AMD cohort and the matched control population for the CFHR1 
allotypes. In addition, we included in these studies the analysis of other polymorphisms 
that had been previously associated with AMD3-10, 13 (see Materials and Methods). The 
allelic frequencies of each of these polymorphisms were determined and compared 
between the two groups (Table 1). In agreement with previous studies we have found 
strong positive associations between the alleles CFH-402His, CFH-c.2237-543G and 
ARMS2-69Ser and AMD, and a strong protective association of CFH-62Ile, CFB-9His 
and CFB-32Gln/Trp with AMD. C3-102Gly, previously found associated with AMD, 
shows a similar positive trend in our population that was not statistically significant. 
Interestingly, the three CFHR1 alleles show very distinct associations with AMD. A 
very strong and significant association was found between AMD and the CFHR1 
allotype CFHR1*A (OR= 2.08, 95% CI 1.59-2.73), whereas no significant differences 
in the frequency of the CFHR1*B allele were found between AMD patients and controls 
(0.34 vs 0.38). As previously reported, the third CFHR1 allele ΔCFHR3-CFHR1 shows a 
very significant protective effect for AMD (OR= 0.34, 95% CI 0.23-0.50) (Table 1). 
The associations between the six CFHR1 genotypes and AMD are depicted in Table 2. 
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CFHR1*A show a very strong positive association with AMD, but only when this allele 
is in homozygosis (OR= 3.08, 95% CI 1.92-4.92). Interestingly, the positive association 
of the CFHR1*A allele with AMD disappear in the CFHR1*A-CFHR1ΔCFHR3-CFHR1 
heterozygote carriers. In fact, the frequency of these heterozygotes is significantly 
decreased in AMD indicating that this genotype protects against AMD (OR=0.40, 95% 
CI 0.24-0.69). Therefore, the CFHR1ΔCFHR3-CFHR1 allele has a dominant effect over the 
CFHR1*A allele. The CFHR1 genotype data shown in Table 2 confirms the neutral role 
of the CFHR1*B allele in AMD. In agreement with previous reports, the CFHR1ΔCFHR3-
CFHR1 homozygote genotype has a strong AMD protective effect (OR= 0.48, 95% CI 
0.17-1.37), although it is not statistically significant in our study due to the reduced size 
of our control and patient cohorts. 
 
CFHR1*A is in strong linkage disequilibrium with CFH 402His. 
Strong linkage disequilibrium across the CFH-CFHR3-CFHR1 genes has been 
described earlier24, 27. Consistently with these findings we found strong linkage 
disequilibrium between SNPs in the CFH gene and the CFHR1 alleles in both the AMD 
and control populations (Figure 2), which further illustrate that the CFH haplotypes 
associated with AMD extend away from the CFH gene to include the CFHR1 alleles. 
Comparison of the frequencies for these extended haplotypes (including the CFH, 
CFHR3 and CFHR1 genes) between the AMD and the control cohorts demonstrated 
three mayor extended haplotypes associated with risk or protection to AMD that 
correlate well with the CFHR1 alleles. Accordingly, CFHR1ΔCFHR3-CFHR1 occurs 
predominantly on an extended haplotype that includes the AMD protective CFH 
haplotype H4, CFHR1*A is in strong linkage disequilibrium with the AMD risk allele 
CFH-402His and occurs predominantly in the AMD risk CFH haplotype H1, and 
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CFHR1*B distributes almost equally between two extended haplotypes, one including 
the protective CFH haplotype H2 and another including the neutral CFH haplotype H3 
(Figure 2). It is also interesting that the CFH-402His and CFHR1*A alleles shows much 
stronger linkage disequilibrium in controls than in AMD patients (0.90 vs 0.78) (Table 
3). This could be related to the slight increase of some minoritary haplotypes carrying 
CFHR1*A without CFH-402His in the AMD cohort (Figure 3). If confirmed, these data 
would emphasize the relevance of CFHR1 for the association of this extended CFH 
haplotype with AMD.  
 
Usefulness of the CFHR1 genotypes in the calculation of AMD risk scores and 
probability of AMD development. 
To evaluate the relevance of the CFHR1 genotypes in assessing the predictability of 
AMD development, we compared two alternative models including different sets of 
polymorphisms associated with AMD in the Spanish population. Model 1, considers the 
CFH Tyr402His genotypes together with those of the CFB Leu9His, CFB 
Arg32Gln/Trp, ARMS2 Ala69Ser and ΔCFHR3-CFHR1 polymorphisms. Model 2, is based 
on the genotypes at the triallelic locus CFHR1 in addition to the genotypes of the CFB 
Leu9His, CFB Arg32Gln/Trp and ARMS2 Ala69Ser polymorphisms. We have used 
multivariate logistic regression analysis and ROC statistics for the calculation of the 
AMD risk scores and the probability of AMD development using these two models 
(Table 4; Figure 3). Regression coefficients (risk scores) for all the genotypes were 
determined comparing their frequencies in cases and controls for the two models (Table 
4).  To assess the cumulative AMD risk scores (Z) for each individual we simply added 
the risk scores (α and β regression coefficients) obtained in the multivariate logistic 
regression analysis (Table 4) for each of the genotypes carried by the individual. The 
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ROC curve analysis showed no significant differences between both models (AUC 
values: 0.79 vs 0.78) in assessing the predictability of AMD (Figure 3). Furthermore, at 
the appropriate cumulative risk score cut-offs, both models yielded virtually identical 
sensitivities and specificities of approximately 70%. Therefore, the CFHR1 genotypes 
provide as meaningful predictive values for AMD as the CFH Tyr402His and ΔCFHR3-
CFHR1 genotypes. 
Figure 3b shows a plot of the individual probabilities (P) of developing AMD, 
calculated from the cumulative AMD risks scores for model 2 (see Materials and 
Methods).  In general, cases had higher probabilities than controls.  To illustrate this 
better we categorized the probabilities in four groups of risk: very low (VL; P<25%), 
low (L; 25%>P<50%), high (H; 50%>P<75%) and very high (VH; P>75%). As 
expected, the controls with no sign of AMD tend to cluster in the low risk groups, 
whereas our AMD cases fell predominantly into the high-risk groups (Figure 3c).   
AMD shows a prevalence of 25% in the general Spanish population older than 80 
years31. We have used this figure and the frequency distribution of cases and controls in 
the four risk categories to simulate the frequencies of AMD cases within each risk 
category in the general population and thus to provide an estimation of the relative risk 
to have AMD by 80 years-old of the individuals in each category (Figure 4). Under this 
model an individual in the very low-risk (VL) category has a 10-fold lower relative risk 
for AMD that one in the very high-risk (VH) category. The overall population 
prevalence of 25% was exceeded only in the two highest-risk groups (H and VH), with 
an estimated AMD prevalence rising to 61% for those in the VH risk group. This risk 
group represents approximately 18% of the general population over 80 years-old.   
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DISCUSSION 
Here we report that CFHR1*A, a recently described allele in the CFHR1 gene, is over-
represented in AMD patients (OR, 2.08; 95% CI, 1.59-2.73; P<0.0001) and included in 
the risk haplotype carrying the CFH-402His allele. The identification of CFHR1*A as a 
risk factor for AMD is consistent with the strong AMD protective effect associated with 
the deletion of this gene and suggests a relevant role for CFHR1 in AMD pathogenesis. 
Moreover, our findings illustrate a distinct association of the CFHR1 alleles with AMD 
and other diseases, like atypical Hemolytic Uremic Syndrome, which may provide 
insights into AMD pathogenesis. Further, we demonstrate the value of CFHR1 
genotyping in prediction of AMD risk.  
AMD has a strong genetic component with a major susceptibility locus encompassing 
the CFH, CFHR3 and CFHR1 genes within the Regulators of Complement Activation 
(RCA) gene cluster in 1q31. Strong linkage disequilibrium at this genomic region limit 
the genetic variability to a small set of extended CFH haplotypes, which includes one 
haplotype conferring increased risk and two haplotypes that protect from AMD. CFH-
402His, CFH-62Ile and ΔCFHR3-CFHR1, respectively, are considered the genetic variations 
within each of these extended CFH haplotype responsible for the association with 
AMD23. The CFH Tyr402His polymorphism, in particular, has been extensively studied 
from a functional point of view. These studies indicated that this amino acid substitution 
alters the binding specificity of factor H for different glycosaminoglycans19-20 and 
decreases its binding to retinal pigment epithelial cells21 and Bruch membrane22. 
However, the physiological relevance of these observations is still unclear. In contrast, 
the factor H 62Ile variant, showing increased complement regulatory activity, likely 
confers lower risk to AMD by reducing complement activation16. 
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In close proximity to CFH, within the extended CFH haplotypes, are CFHR1 and 
CFHR3, two genes coding for proteins showing sequence and structural homology to 
factor H (Figure 1). CFHR3 and CFHR1 are both complement regulators that compete 
with factor H for binding to C3b. CFHR1 acts downstream of factor H and inhibits the 
C5-convertase and the lytic pathway, while CFHR3 acts as a cofactor for factor I in 
inactivating C3b26-27. Based on the reported functional activities of CFHR1 and CFHR3 
it seems paradoxical that the loss of these two complement regulators strongly protects 
against AMD. On the other side, it has been consistently found that ΔCFHR3-CFHR1 is an 
independent protective factor for AMD, which suggest that CFHR3 and/or CFHR1 
protein function confers risk to AMD.  
The concept that CFHR1 confers risk to AMD is further supported by our findings that 
CFHR1 encodes two major alleles, CFHR1*A and CFHR1*B alleles with different 
degree of similarity with factor H, which associated differentially with disease29. We 
have shown earlier that homozygosity for the CFHR1*B allotype, with greater sequence 
similarity to factor H, is strongly associated with atypical hemolytic uremic syndrome 
(aHUS) (OR=2.54; 95% CI 1.36-4.73; P=0.0032) and suggested that increased 
competition between CFHR1*B and factor H decreases protection by factor H of 
cellular surfaces against complement damage29. Here we show that CFHR1*A, which is 
neutral in aHUS, is strongly associated with AMD in homozygosis (OR=3.08; 95% CI 
1.92-4.92; P<0.0001). Interestingly, the association of both CFHR1*B with aHUS and 
CFHR1*A with AMD seems to be dose dependent, as they disappear if only one allele 
is preset (CFHR1*B/CFHR1ΔCFHR3-CFHR1 or CFHR1*A/CFHR1ΔCFHR3-CFHR1 
heterozygotes). This indicates that the CFHR1ΔCFHR3-CFHR allele is protective in both 
aHUS and AMD, despite homozygotes CFHR1ΔCFHR3-CFHR are increased in aHUS due 
to the association with anti factor H autoantibodies26-27. A last relevant observation from 
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our association studies is that CFHR1*A/CFHR1*B heterozygotes are not increased in 
AMD and aHUS. If we assume that CFHR1 proteins associate with disease because of 
competition with factor H, these data suggests that the CFHR1*A and CFHR1*B allele 
may compete distinct functional activities in factor H that are essential in the 
pathogenesis of one or other disorder. Detailed functional analyses of the CFHR1*A 
and CFHR1*B allele would be needed to determine whether this hypothesis is correct. 
Despite these uncertainties, our genetic analysis of CFHR1 in AMD suggests that 
models based on CFHR1 genotypes should provide meaningful predictive values for the 
development of AMD. The results presented here probe this suggestion to be correct. In 
fact, our model of disease risk based on the CFHR1, CFB and ARMS2 genotypes works 
well in assessing the predictability of AMD (Figure 3) with AUC values of 0.78 and 
sensitivities and specificities of approximately 70%. These are significant values for a 
model based exclusively on genetic markers. Relatives of AMD patients and individuals 
with very early-stage disease signs may benefit from knowing their genetic risk as this 
may anticipate diagnosis and potential treatments.  
 
Conclusions and limitations of the study. 
We show here that the CFHR1*A allele is strongly associated with AMD. These novel 
data and previous studies in our laboratory29 demonstrate a differential association of 
the two major CFHR1 allotypes, CFHR1*A and CFHR1*B, with AMD and aHUS, 
respectively, which suggests that CFHR1 play a relevant role in these pathologies. In 
fact, and despite CFHR1*A is in strong linkage disequilibrium with the CFH-402His 
allele, our data support that CFHR1*A is a strong candidate within the mayor risk 
haplotype at 1q32 for being responsible for the association with AMD. However, our 
study has limitations. It includes a relatively small case-control cohort, which prevent us 
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to determine whether the CFHR1*A variant remains significantly associated with AMD 
after removing the CFH-402His-carrying haplotypes. Additional studies and further 
understanding of the functional activities of CFHR1, including the potential differences 
between the CFHR1*A and CFHR1*B allotypes, may help to determine whether the 
CFHR1 genotypes are more relevant to AMD than the CFH Tyr402His variant. 
Meanwhile, we have tested the usefulness of CFHR1 to generate models of disease risk 
and demonstrated that the CFHR1 genotypes provide meaningful predictive values for 
the development of AMD. 
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Table 1. Polymorphisms in the CFH, CFB, C3, CFHR1 and ARMS2 genes associated with  AMD. 
 
  Allele frequencies   
Gene (SNP) Allele Controls 
(n=191) 
AMD 
(n=259) 
p_value OR (95% CI) 
CFH (rs88292) c.62Ile 0.25 0.14 <0.0001 0.48 (0.34-0.67) 
CFH (rs1061170) c.402His 0.29 0.49 <0.0001 2.27 (1,71-3.00) 
CFH (rs1410996) c.2237-543G 0.55 0.76 <0.0001 3.96 (2.98-5.30) 
CFB (rs4151667) c.9His 0.04 0.02 0.0087 0.34 (0.14-0.79) 
CFB (rs12614; rs64115; rs641153) c.32Gln/Trp 0.26 0.19 0.0093 0.66 (0.48-0.90) 
ARMS2 (rs10490924) c.69Ala  0.8 0.55 <0.0001 0.30 (0.22-0.41) 
 CFHR1*A 0.39 0.57 <0.0001 2.08 (1.59-2.73) 
CFHR1 CFHR1*B 0.38 0.34 0.176 0.83 (0.63-1.09) 
 ΔCFHR1-CFHR3 0.23 0.09 <0.0001 0.34 (0.23-0.50) 
C3 (rs4151667) c.102Gly 0.2 0.24 0.094 1.32 (0.95-1.82) 
 
The nomenclature of the polymorphisms is referred to the transcription start site (+1) of each gene. Alleles at the CFHR1 gene are as described in the text. The P_value is the 
result of a two-sided Pearson’s Chi-square test of association for the comparison of the allelic frequencies between the AMD and control groups. 
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TABLE 2. CFHR1  genotypes associated with AMD 
 
 
 
  
 Controls (n=191) AMD (n=259)   
Genotype n frecuency n frequency P_value OR ( 95%CI ) 
CFHR1*A   /   CFHR1*A  29 0.15 92 0.36 <0.0001 3.08 (1.92-4.92) 
CFHR1*B  /   CFHR1*B  32 0.17 38 0.15 0.55 0.85 (0.51-1.43) 
ΔCFHR1-CFHR3 /ΔCFHR1-CFHR3 9 0.05 6 0.02 0.16 0.48 (0.17-1.37) 
CFHR1*A  /  ΔCFHR1-CFHR3 40 0.21 25 0.1 0.0008 0.40 (0.24-0.69) 
  CFHR1*B  /  ΔCFHR1-CFHR3 30 0.16 11 0.04 <0.0001 0.39 (0.12-0.49) 
CFHR1*A  /  CFHR1*B  51 0.27 87 0.34 0.12 1.39 (0.92-2.09) 
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TABLE 3. Linkage disequilibrium analysis between CFH SNPs and CFHR1 alleles 
 
 CONTROLS   AMD  
A D'=0,52 r2=0,06  A 
D'=0,64 
r2=0,09 
B D'=-0,62 r2=0,21  B 
D'=-0,55 
r2=0,10 
CFH 
(rs88292) 
c.62Val 
D'=0,77 
r2=0,08 
D'=0,83 
r2=0,29 
ΔR3R1 
D'=-0,81 
r2=0,07  
CFH 
(rs88292) 
c.62Val 
D'=0,95 
r2=0,14 
D'=0,92 
r2=0,45 
ΔR3R1 
D'=-0,01 
r2=0,00 
 A D'=0,90 r2=0,53   A 
D'=0,78 
r2=0,43 
 B D'=-0,82 r2=0,17   B 
D'=-0,76 
r2=0,28 
 
CFH 
(rs106117) 
c.402His 
D'=0,91 
r2=0,28 
ΔR3R1 
D'=-1 
r2=0,12   
CFH 
(rs106117) 
c.402His 
D'=0,86 
r2=0,22 
ΔR3R1 
D'=-0,77 
r2=0,51 
  A D'=0,83 r2=0,36    A 
D'=0,63 
r2=0,17 
  B D'=-0,12 r2=0,01    B 
D'=-0,13 
r2=0,01 
  
CFH 
(rs1410996) 
c.2237-543G 
 
ΔR3R1 
D'=-0,89 
r2=0,29    
CFH 
(rs1410996) 
c.2237-543G 
ΔR3R1 
D'=-0,97 
r2=0,23 
       
       
   
CFHR1 
 
    
CFHR1 
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Table 4. Logistic regression models. 
 
 
 
   Model 1 (402His; ΔCFHR3-CFHR1)  Model 2 (CFHR1) 
Gen (polymorphism) Genotype  
Regression coefficient 
(β) P_value OR (95%CI)  
Regression coefficient 
(β) P_value OR (95%CI) 
CFB (L9H) L/L  0    0   
 L/H  -1.114 0.018 0.32 (0.12-0.82)  -1.084 0.023 0.34 (0.13-0.86) 
CFB (R32Q/W) R/R  0.632 0.252 1.88 (0.64-5.54)  0.552 0.317 1.73 (0.60-5.11) 
 R/Q or W  -0.284 0.613 0.75 (0.25-2.26)  -0.359 0.524 0.70 (0.23-2.10) 
 Q or W/Q or W  0    0   
ARMS2 (A69S) A/A  0    0   
 A/S  0.960 <0.001 2.61 (1.64-4.16)  0.963 <0.001 2.62 (1.65-4.15) 
 S/S  2.148 <0.001 8.57 (3.89-18.8)  2.223 <0.001 9.23 (4.19-20.3) 
CFH (Y402H) Y/Y  0    - - - 
 Y/H  0.585 0.017 1.79 (1.11-2.90)  - - - 
 H/H  1.178 0.001 3.25 (1.60-6.61)  - - - 
ΔCFHR3-CFHR1 Del/Del  -1.577 0.025 0.21 (0.05-0.80)  - - - 
 Del/wt  -1.029 <0.001 0.36 (0.21-0.60)  - - - 
 wt/wt  0    - - - 
CFHR1 (A/B/ΔCFHR3-CFHR1) A/A  - - -  0.992 0.004 2.69 (1.37-5.31) 
 B/B  - - -  0   
 Del/Del  - - -  -1.041 0.102 0.35 (0.10-1.23) 
 A/B  - - -  0.525 0.111 1.69 (0.88-3.23) 
 A/Del  - - -  -0.538 0.157 0.58 (0.28-1.23) 
 B/Del  - - -  -1.012 0.026 0.36 (0.15-0.89) 
 Constant (α)  -0.678    -0.658   
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FIGURE LEGENDS 
 
Figure 1. Structural similarities between the CFHR1 alleles and factor H 
Schematic representation of the structural organization of factor H and the CFHR1*A 
and CFHR1*B. Short consensus repeats (SCRs) are represented by circles and are 
numbered from the N-ternimal end. Homologous SCRs are aligned and the amino acid 
differences with factor H indicated for SCR-3, -4 and -5 of CFHR1*A and CFHR1*B. 
SCR 1 and 2 of CFHR1 show only a 41% homology with factor H. The homologous 
position to factor H 402His in both CFHR1*A and CFHR1*B is 100Ser. 
 
Figure 2: CFH-CFHR3-CFHR1 haplotypes and their association with AMD. 
Figure shows the exon structure of CFH, CFHR3 and CFHR1 showing the location of 
the polymorphism included in these studies. Exon 10, characyteristic of the alternative 
spliced protein CFHL1 is depicted in green. Haplotype frequencies in the control and 
patient cohorts were estimated using the EM algorithm (Expectation Maximization 
algorithm) implemented by the SNPStats software available on-line at 
(http://bioinfo.iconcologia.net/SNPstats). CFH haplotypes with a frequency >1% are 
shown. The frequency of each CFH haplotype was compared between the controls and 
the AMD cohorts and the p-values and the OR were calculated. Risk haplotypes are 
shaded in red whilst protective haplotypes are shaded in green. p-values were derived 
using Pearson’s Chi-square test of association. Odds ratio (OR) and 95% confidence 
intervals (CI) are shown. The nucleotide and amino acid numbering are referred to the 
translation start site (A in ATG is +1; Met is +1) as recommended by the Human 
Genome Variation Society (HGVS). 
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Figure 3: Model of disease risk based on CFHR1, CFB and ARMS2 genotypes 
A) Comparison of disease risk models. Model 1 (based on genotypes of the CFH 
Tyr402His, ΔCFHR3-CFHR1, CFB Leu9His, CFB Arg32Gln/Trp and ARMS2 
Ala69Ser polymorphisms). Model 2 (based on genotypes of the CFHR1, CFB 
Leu9His, CFB Arg32Gln/Trp and ARMS2 Ala69Ser  polymorphisms). The ROC 
curve analysis showed no significant differences between both models (AUC 
values: 0.79 vs 0.78) in assessing the predictability of AMD. Optimal risk cut-
offs provide sensitivities and specificities of approximately 70% for both 
models. 
B) Dot diagram for the distribution of cases and controls for model 2. Risk 
categories were established as described in Materials and Methods. 
C) Distribution of Spanish AMD cases and controls according to their frequencies 
in the risk groups. Risk categories were established as described in Materials and 
Methods. 
 
Figure 4: Distribution of AMD cases and healthy individuals in the >80y old 
Spanish population according to their predicted distribution in the risk groups and 
on a prevalence of AMD of 25%.  
Percentages of AMD (black) cases and healthy individuals (white) within each group 
are indicated. 
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